Published finding — does the expert body still believe it?
The EMERGE (aducanumab) trial's stated primary conclusion — Aducanumab’s pivotal phase 3 showed mixed evidence for cognitive slowing in early Alzheimer disease. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0821
Recent follow-up analyses of EMERGE (aducanumab) are confirming the original effect size in real-world data.
0.0942
The CLARITY-AD (lecanemab) trial's stated primary conclusion — Lecanemab slows cognitive decline in early Alzheimer disease with amyloid confirmation, with a non-trivial ARIA safety signal. — replicates in independent cohorts.
0.1452
Recent follow-up analyses of CLARITY-AD (lecanemab) are confirming the original effect size in real-world data.
0.1953
By 2028, anti-amyloid antibodies will have a net positive impact on real-world CDR-SB trajectories, but uptake will remain <25% of eligible early AD patients due to ARIA monitoring burden.
0.2088
By 2028, aducanumab will have been withdrawn or deprioritized in favor of later anti-amyloid agents with cleaner efficacy signals.
0.2294
Recent follow-up analyses of EARLYSTIM are confirming the original effect size in real-world data.